Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00638612 · ClinicalTrials.gov registry record · Phase 1
AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)
A Phase 1 study, sponsored by Candel Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT00638612 is a Phase 1 study that has completed, run by Candel Therapeutics. The registered enrollment target is 27 participants.
The verdict
NCT00638612, a Phase 1 study, has completed, sponsored by Candel Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of this Phase 1 study is to evaluate the safety and potential efficacy of Gene Mediated Cytotoxic Immunotherapy for pancreatic cancer. The approach uses an adenoviral vector (disabled virus) engineered to express the Herpes thymidine kinase gene (AdV-tk), followed by an antiherpetic prodrug, valacyclovir.
Interventions
- DRUG Valacyclovir
- BIOLOGICAL AdV-tk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2008-08 |
| Est. Completion | 2015-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00638612
The ClinicalTrials.gov registry entry for NCT00638612 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Candel Therapeutics, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Valacyclovir is the first listed.
NCT00638612 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00638612 about?
NCT00638612 is a clinical study titled "AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)". The purpose of this Phase 1 study is to evaluate the safety and potential efficacy of Gene Mediated Cytotoxic Immunotherapy for pancreatic cancer. The approach uses an adenoviral vector (disabled virus) engineered to express the Herpes thymidine kinase gene (AdV-tk), followed by an antiherpetic prod...
What is the current status of trial NCT00638612?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2008-08. Estimated completion is 2015-06.
What interventions are being tested in trial NCT00638612?
The interventions under investigation include: Valacyclovir (DRUG), AdV-tk (BIOLOGICAL).
Who is sponsoring clinical trial NCT00638612?
This trial is sponsored by Candel Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.